{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:29:30Z","timestamp":1788370170827,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.yebeh.2016.07.034","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T20:52:05Z","timestamp":1472849525000},"page":"79-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex"],"prefix":"10.1016","volume":"63","author":[{"given":"Aria","family":"Fallah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Weil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine B.","family":"Baca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary W.","family":"Mathern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2016.07.034_bb0005","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/S0140-6736(05)78872-3","article-title":"Prevalence of tuberous sclerosis estimated by capture\u2013recapture analysis","volume":"351","author":"O'Callaghan","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0010","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1212\/WNL.35.4.600","article-title":"Incidence and prevalence of tuberous sclerosis in Rochester, Minnesota, 1950 through 1982","volume":"35","author":"Wiederholt","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","article-title":"Tuberous sclerosis","volume":"372","author":"Curatolo","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1528-1167.2006.00440.x","article-title":"Defining intractability: comparisons among published definitions","volume":"47","author":"Berg","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0025","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1528-1167.2009.02474.x","article-title":"The natural history of epilepsy in tuberous sclerosis complex","volume":"51","author":"Chu-Shore","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1528-1157.1998.tb01164.x","article-title":"Uptake and costs of care for epilepsy: findings from a U.K. regional study","volume":"39","author":"Jacoby","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0035","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/j.1528-1157.1994.tb01794.x","article-title":"Cost of epilepsy in the United States: a model based on incidence and prognosis","volume":"35","author":"Begley","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eplepsyres.2011.01.005","article-title":"Cost-effectiveness of pediatric epilepsy surgery compared to medical treatment in children with intractable epilepsy","volume":"94","author":"Widjaja","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053565","article-title":"Predictors of seizure outcomes in children with tuberous sclerosis complex and intractable epilepsy undergoing resective epilepsy surgery: an individual participant data meta-analysis","volume":"8","author":"Fallah","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0050","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1227\/NEU.0000000000000875","article-title":"Resective epilepsy surgery for tuberous sclerosis in children: determining predictors of seizure outcomes in a multicenter retrospective cohort study","volume":"77","author":"Fallah","year":"2015","journal-title":"Neurosurgery"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0055","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/j.1528-1167.2007.01117.x","article-title":"Epilepsy surgery in tuberous sclerosis: a systematic review","volume":"48","author":"Jansen","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0065","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0070","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/jama.1996.03540150055031","article-title":"Recommendations of the panel on cost-effectiveness in health and medicine","volume":"276","author":"Weinstein","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0075","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0080","series-title":"Surgical treatment of the epilepsies: outcome with respect to epileptic seizures","author":"Engel","year":"1987"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0085","first-page":"1","article-title":"Epilepsy care in Ontario: an economic analysis of increasing access to epilepsy surgery","volume":"12","author":"Bowen","year":"2012","journal-title":"Ont Health Technol Assess Ser"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0090","series-title":"Cost-effectiveness in health and medicine","author":"Gold","year":"1996"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0095","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0115","series-title":"Designing and conducting cost-effectiveness analyses in medicine and health care","author":"Muennig","year":"2002"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0120","unstructured":"U.S. Department of Labor BoLS. In; Consumer Price Index Calculator."},{"key":"10.1016\/j.yebeh.2016.07.034_bb0140","series-title":"2016 AMA CPT professional edition book","author":"Association AM","year":"2016"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.seizure.2014.10.014","article-title":"Vagus nerve stimulation therapy in a developing country: a long term follow up study and cost utility analysis","volume":"25","author":"Aburahma","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0150","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eplepsyres.2014.12.005","article-title":"Cost-effectiveness of the ketogenic diet and vagus nerve stimulation for the treatment of children with intractable epilepsy","volume":"110","author":"de Kinderen","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1059-1311(02)00270-4","article-title":"Cost-utility analysis of vagus nerve stimulators for adults with medically refractory epilepsy","volume":"12","author":"Forbes","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0165","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1528-1167.2007.01466.x","article-title":"Health resource use in epilepsy: significant disparities by age, gender, and aboriginal status","volume":"49","author":"Jette","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1528-1157.1997.tb01091.x","article-title":"Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy","volume":"38","author":"Langfitt","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0175","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1111\/epi.12371","article-title":"Predictors of seizure-free outcome after epilepsy surgery for pediatric tuberous sclerosis complex","volume":"54","author":"Krsek","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0180","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00381-008-0679-4","article-title":"Epilepsy surgery in tuberous sclerosis complex: early predictive elements and outcome","volume":"24","author":"Teutonico","year":"2008","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0185","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.yebeh.2009.08.018","article-title":"Refractory epilepsy in tuberous sclerosis: vagus nerve stimulation with or without subsequent resective surgery","volume":"16","author":"Elliott","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2011.2.PEDS10505","article-title":"Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases","volume":"7","author":"Elliott","year":"2011","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0195","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3171\/2011.7.JNS11977","article-title":"Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response","volume":"115","author":"Englot","year":"2011","journal-title":"J Neurosurg"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1684\/epd.2015.0768","article-title":"Vagus nerve stimulation in children with drug-resistant epilepsy: age at implantation and shorter duration of epilepsy as predictors of better efficacy?","volume":"17","author":"Lagae","year":"2015","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0205","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.yebeh.2008.04.001","article-title":"Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex","volume":"13","author":"Major","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0210","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.seizure.2011.06.009","article-title":"Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients","volume":"20","author":"Caraballo","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0215","first-page":"276","article-title":"Prospective multicenter study on long-term ketogenic diet therapy for intractable childhood epilepsy","volume":"51","author":"Ketogenic Diet Study Group of the Subspecialty Group of Neurology tSoPCMA","year":"2013","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0220","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1474-4422(08)70092-9","article-title":"The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial","volume":"7","author":"Neal","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0225","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1111\/j.1528-1167.2011.03394.x","article-title":"Efficacy of the ketogenic diet: which epilepsies respond?","volume":"53","author":"Thammongkol","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0230","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.eplepsyres.2012.01.015","article-title":"Is the ketogenic diet effective in specific epilepsy syndromes?","volume":"100","author":"Nangia","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0235","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jpeds.2013.12.053","article-title":"Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex","volume":"164","author":"Cardamone","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0240","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejpn.2013.03.002","article-title":"Long-term effect of everolimus on epilepsy and growth in children under 3years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex","volume":"17","author":"Kotulska","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0245","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/ana.23960","article-title":"Everolimus treatment of refractory epilepsy in tuberous sclerosis complex","volume":"74","author":"Krueger","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0250","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/0272989X05280559","article-title":"Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: the results of a probabilistic decision model","volume":"25","author":"Hawkins","year":"2005","journal-title":"Med Decis Making"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0255","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1098-3015(10)61359-9","article-title":"Evaluation of the relationship between epilepsy severity and utility","volume":"5","author":"Selai","year":"2002","journal-title":"Value Health"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0260","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s002280050402","article-title":"Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis","volume":"53","author":"Messori","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0265","doi-asserted-by":"crossref","first-page":"185","DOI":"10.4306\/pi.2009.6.3.185","article-title":"Economic evaluation of add-on levetiracetam for the treatment of refractory partial epilepsy in Korea","volume":"6","author":"Suh","year":"2009","journal-title":"Psychiatry Investig"},{"key":"10.1016\/j.yebeh.2016.07.034_bb0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.yebeh.2015.10.006","article-title":"Moving beyond evidence-based medicine: incorporating patient values and preferences","volume":"53","author":"Fallah","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016303043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505016303043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T15:11:53Z","timestamp":1601046713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505016303043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":47,"alternative-id":["S1525505016303043"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.07.034","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-utility analysis of competing treatment strategies for drug-resistant epilepsy in children with Tuberous Sclerosis Complex","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2016.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}